Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocumension TherapeuticsOCUTF 53 10-Year Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates OCUTF with a GF Score™ of 53/100 and a GF Value™ of $2.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 668 Biotechnology companies, Ocumension Therapeutics ranks worse than 149700.45% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Ocumension Therapeutics's current 10-Year Share Buyback Ratio was 0.00%.
OCUTF's 10-Year Share Buyback Ratio is not ranked *
in the Biotechnology industry.
Industry Median: -11.65 * Ranked among companies with meaningful 10-Year Share Buyback Ratio only.
Ocumension Therapeutics (OTCPK:OCUTF) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Ocumension Therapeutics 10-Year Share Buyback Ratio Related Terms
OCUTF vs VRTX, REGN, RVMD: 10-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics 10-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's 10-Year Share Buyback Ratio falls into.
Ocumension Therapeutics 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of 0.00 mean?
Ocumension Therapeutics (OCUTF) has a 10-Year Share Buyback Ratio of 0.00 as of Dec. 2025. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Ocumension Therapeutics and its competitors. According to the industry distribution chart, Ocumension Therapeutics ranks #999999 out of 668 companies in the Biotechnology industry.
Is Ocumension Therapeutics' 10-Year Share Buyback Ratio too high?
Ocumension Therapeutics' current 10-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Ocumension Therapeutics ranks #999999 out of 668 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ocumension Therapeutics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' 10-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #999999 out of 668 companies for 10-Year Share Buyback Ratio. This places Ocumension Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Ocumension Therapeutics and its competitors. Ocumension Therapeutics's current 10-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.61, compared to a current price of $0.70 — trading 73.2% below its estimated fair value. The current 10-Year Share Buyback Ratio is 0.00. Ocumension Therapeutics' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current 10-Year Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 73.2% below its estimated GF Value™ of $2.61.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
10-Year Share Buyback Ratio: 0.00
GF Value™: $2.61 vs. price of $0.70 (73.2% below fair value)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
53GF Score
Get the complete analysis for OCUTF
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
